Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Get the latest S&P 500 healthcare stock winners & losers, major earnings beats, profit forecasts, and legal news for key companies.

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

In late October 2025, Point32Health, Massachusetts’ second-largest health insurer, announced its second major round of ...

New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating disease.

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...